EP1414423A1 - Agent de traitement de troubles depressifs contenant un anesthesique local - Google Patents

Agent de traitement de troubles depressifs contenant un anesthesique local

Info

Publication number
EP1414423A1
EP1414423A1 EP01960129A EP01960129A EP1414423A1 EP 1414423 A1 EP1414423 A1 EP 1414423A1 EP 01960129 A EP01960129 A EP 01960129A EP 01960129 A EP01960129 A EP 01960129A EP 1414423 A1 EP1414423 A1 EP 1414423A1
Authority
EP
European Patent Office
Prior art keywords
brain
substance
composition according
nerve cells
increases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01960129A
Other languages
German (de)
English (en)
Inventor
Lothar Saiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1414423A1 publication Critical patent/EP1414423A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the invention relates to an agent for the manufacture of a medicament for the treatment of depression.
  • depression is usually caused by a depletion of biochemical or messenger substances or neurotransmitters such as dopamine, noradrenaline and serotonin.
  • Depression is experienced subjectively by the individuals concerned as a feeling of general powerlessness, this feeling being caused consciously or unconsciously by a restriction of the subjective brain performance. If a person does not consciously perceive a restriction of their own brain performance, a general lack of drive is perceived subjectively compared to other people or also compared to their own earlier phases of life. This results in a feeling of inability to shape one's own life, whereby a life shaped by others is perceived as not meaningful and worth living.
  • the triggering element of the subjective emotional basic mood of a depressed person is therefore the feeling or the recognition of a lack of controllability of the environment or one's own powerlessness and the resulting unimportance or superfluousness of one's own person.
  • the reason for this, namely the restriction of one's own brain performance, is only perceived personally by some of those affected.
  • the object of the invention is therefore to provide an agent with which depression and the symptoms of depression can be effectively treated.
  • this object is achieved by a local anesthetic from the anilide group.
  • the substance mepivacaine is selected as the local anesthetic of the anilide group, preferably in a daily dose of 30 mg to 60 mg.
  • the substances lidocaine, bupivacaine, butanilicaine, tholycaine or etidocaine can be used.
  • an activation of the intercellular communication of the cerebral nerve cells of a depressed person is achieved quintessentially by the combination of active ingredients of a substance increasing the dopamine concentration in the synaptic gap of the nerve cells of the brain and a local anesthetic of the anilide group or its derivatives.
  • Serotonin plays an important role in depression. Serotonin is the so-called happiness hormone, whereby a person feels happy with a given concentration of serotonin in the brain or at least does not feel depressed. There is an empirical relationship between the serotonin concentration and the dopamine concentration in the brain.
  • Depression is particularly attributable to a malfunction of the so-called parasympatic system and / or the sympathetic system of the human brain.
  • the parasympathetic system controls the body's energy-building processes such as sleep, digestion and relaxation. It leads to lower blood pressure, heart rate reduction and converts glucose into glycogen. Serotonin is predominantly the neurotransmitter in the parasympathetic system.
  • the sympathetic system is used to control energy-consuming processes such as heart activation, increased blood pressure and blood sugar mobilization.
  • the neurotransmitter in the sympathetic system is predominantly norepinephrine.
  • Adequate provision of a concentration of dopamine, norepinephrine and serotonin in the brain required for normal brain function can be treated according to the invention by targeted administration of a local anesthetic from the anilide group.
  • a local anesthetic from the anilide group.
  • the permeability of the blood / brain barrier is increased in such a way that L-dopa can increasingly pass through this barrier and get into the brain.
  • L-dopa is a substance that is converted to dopamine in the substantia nigra, another area of the brain.
  • dopamine is a precursor to the formation of serotonin and norepinephrine.
  • the agent according to the invention causes an increase in the transmission potential of the connections of nerve cells, in particular those of the brain.
  • the combination of a substance that increases the dopamine concentration in the synaptic gap of the nerve cells of the brain with a local anesthetic from the anilide group causes the permeability of the blood-brain barrier for the substance LevoDopa to be increased, so that dopamine is accumulative in higher concentrations than with current standard therapy in the brain of patients suffering from depression people, which consequently a higher concentration of dopamine in the brain • these persons is reached.
  • the substance "local anesthetic of the anilide group" for Parkinson's therapy which is essential to the invention, generally belongs to the local anesthetics of different structure, the local anesthetics of the anilide group and their derivatives being preferred for therapy as a subgroup of these local anesthetics.
  • examples of this subgroup are Ropivacaine.
  • the smallest molecule in this group has mepivacaine, and this substance has also been shown to be most effective in the treatment of Parkinson's disease patients.
  • Mepivacaine is also lipophilic, meaning fat-loving and likes to attach to fat molecules.
  • nerve cells are mostly embedded in fat and that the addition or accumulation of mepivacaine in fat is likely to have an impact on the nerve pathways through the fatty tissue.
  • LevoDopa like Mepivacaine, also has a strong lipophilicity, so that a possible mechanism of action is also given in this connection.
  • In. LevoDopa is preferably applied to the agent according to the invention for the manufacture of a medicament for the treatment of depression in a daily dose of 200 mg to 600 mg.
  • the substance which increases the dopamine concentration in the synaptic gap of the nerve cells of the brain additionally contains bromocriptine, which is preferably applied in a daily dose of 1.25 mg to 10 mg.
  • the substance which increases the dopamine concentration in the synaptic gap of the nerve cells of the brain additionally contains selegiline, which is preferably administered in a daily dose of 4 mg to 20 mg.
  • the substance which increases the dopamine concentration in the synaptic gap of the nerve cells of the brain additionally contains amantadine, which is preferably applied in a daily dose of 100 mg to 400 mg.
  • the substance which increases the dopamine concentration in the synaptic gap of the nerve cells of the brain additionally contains pergolide mesilate, which is preferably applied in a daily dose of 2 mg to 8 mg.
  • the agent according to the invention can also contain tolcapone as a substance which increases the dopamine concentration in the synaptic cleft of the nerve cells of the brain and is applied in a daily dose of 100 mg to 400 mg.
  • the substance which increases the dopamine concentration in the synaptic cleft of the nerve cells of the brain could additionally contain piracetam, which is administered in a daily dose of 1,000 mg to 4,000 mg.
  • the effect of the agent according to the invention is less based on a special combination of increasing the dopamine concentration in the synaptic gap of the brain nerve cells
  • the indicated doses of local anesthetics are related to injection applications. In the case of oral administration, the dosage must be adjusted accordingly.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un agent servant à produire un médicament destiné au traitement de troubles dépressifs. Selon cette invention, une combinaison de principes actifs, composée d'une substance augmentant la concentration de dopamine dans la fente synaptique des cellules nerveuses du cerveau et d'un anesthésique local du groupe anilide, permet d'obtenir un traitement plus efficace que la thérapie classique.
EP01960129A 2001-07-31 2001-07-31 Agent de traitement de troubles depressifs contenant un anesthesique local Withdrawn EP1414423A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/DE2001/002870 WO2003011270A1 (fr) 2001-07-31 2001-07-31 Agent de traitement de troubles depressifs contenant un anesthesique local
PCT/DE2001/002869 WO2003011269A1 (fr) 2001-07-31 2001-07-31 Agent de traitement des symptomes de la demence contenant un anesthesique local supplementaire

Publications (1)

Publication Number Publication Date
EP1414423A1 true EP1414423A1 (fr) 2004-05-06

Family

ID=33030494

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01960129A Withdrawn EP1414423A1 (fr) 2001-07-31 2001-07-31 Agent de traitement de troubles depressifs contenant un anesthesique local
EP01962579A Withdrawn EP1414424A1 (fr) 2001-07-31 2001-07-31 Agent de traitement des symptomes de la demence contenant un anesthesique local supplementaire

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01962579A Withdrawn EP1414424A1 (fr) 2001-07-31 2001-07-31 Agent de traitement des symptomes de la demence contenant un anesthesique local supplementaire

Country Status (3)

Country Link
US (1) US20040192772A1 (fr)
EP (2) EP1414423A1 (fr)
WO (2) WO2003011270A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
AU2014277952A1 (en) * 2013-06-13 2016-01-28 Veroscience Llc Compositions and methods for treating metabolic disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041174A (en) * 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
AU706541B2 (en) * 1995-06-09 1999-06-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
DE19855704C2 (de) * 1998-12-03 2002-08-01 Lothar Saiger Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03011270A1 *

Also Published As

Publication number Publication date
EP1414424A1 (fr) 2004-05-06
WO2003011270A1 (fr) 2003-02-13
WO2003011269A1 (fr) 2003-02-13
US20040192772A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
Lal et al. Modification of function in head-injured patients with Sinemet
de la Fuente-Fernández et al. Placebo mechanisms and reward circuitry: clues from Parkinson's disease
DE69929041T2 (de) Verwendung von cabergolin zur behandlung von "restless legs syndrom"
KRUEGER Restless legs syndrome and periodic movements of sleep
DE69838485T2 (de) Verfahren und vorrichtung zur transdermalen verabreichung von lithium
EP1414423A1 (fr) Agent de traitement de troubles depressifs contenant un anesthesique local
DE69205307T2 (de) Vorrichtung zum Behandeln von Akupunkturpunkten mittels elektrischen Feldern und Medikamentenionen.
CN106853172B (zh) 一种抗抑郁复配精油及其应用
EP1154794B1 (fr) Traitement des symptomes de la maladie de parkinson avec un agent contenant une substance dopaminergique et un anesthesique local du groupe anilide
CN1380071A (zh) 用于治疗精神病和痫病的中药
EP2740480A1 (fr) Procédé destiné à administrer du gaz hypoxique et hyperoxique
HARGROVE et al. The value of subconvulsive electrostimulation in the treatment of some emotional disorders
Dose Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes
EP1140076A1 (fr) Utilisation d'antagonistes de recepteurs de 5ht3 aux fins de traitement du syndrome de fatigue chronique
CN114712276A (zh) 一种舒缓改善肌肤状态的组合物及护肤品
Verebey Opioids and Psycohological Disorders
DE102005032625A1 (de) Arzneimittel zur Behandlung neuronaler und/oder neurodegenerativer Erkrankungen
Pawar et al. TREATMENT OF PSYCHOSIS DISRORDER
DE102005020401A1 (de) Arzneimittel zur Behandlung von Nervenkrankheiten
Pickworth et al. Assessment of mazindol for abuse liability
AT504700A1 (de) Behandlung von angstzuständen
EP0910392A2 (fr) Radicaux a anions oxygene et/ou substances therapeutiques contenant leurs produits de reaction et de degradation et leur utilisation dans le traitement de la maladie de parkinson
Kapoor et al. Drug abuse: Its clinico-pharmacologic and management aspects
Weze et al. Healing by gentle touch in musculoskeletal disorders
Vaughan The role of chlorpromazine in the management of psychiatric patients

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060607